Pablo Villanueva Meyer
Nephrology · Glendale, CANPI 1083076814
Payments from drug & device makers
Across 168 payments — averaging $646.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$77K
- Travere Therapeutics, Inc.$28K
- Aurinia Pharma U.S., Inc.$588
- Bayer$440
- Akebia Therapeutics Inc$390
- Otsuka America Pharmaceutical, Inc.$377
- plus $1K from 13 others
What the payments were for
- Food & beverage$4,22198%
- Education$682%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $77,344 |
| Travere Therapeutics, Inc. | 8 | $28,068 |
| Aurinia Pharma U.S., Inc. | 15 | $588 |
| Bayer | 16 | $440 |
| Akebia Therapeutics Inc | 8 | $390 |
| Otsuka America Pharmaceutical, Inc. | 20 | $377 |
| Amgen(2 entities) | 11 | $335 |
| Mallinckrodt Hospital Products Inc. | 8 | $179 |
| Fresenius USA Marketing, Inc. | 8 | $147 |
| Vifor Pharma, Inc. | 6 | $133 |
| GSK | 5 | $126 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $106 |
| Novo Nordisk | 5 | $102 |
| Calliditas Therapeutics US Inc. | 4 | $74 |
| Boehringer Ingelheim | 2 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $47 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Novartis | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$108,570 in reported general payments places this provider in the 85th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tolvaptan | 15 | $252,563 |
| JardianceEmpagliflozin | 56 | $60,670 |
| VelphoroSucroferric Oxyhydroxide | 15 | $37,960 |
| VeltassaPatiromer Calcium Sorbitex | 34 | $33,403 |
| KerendiaFinerenone | 35 | $26,682 |
| FarxigaDapagliflozin Propanediol | 15 | $17,581 |
| RybelsusSemaglutide | 13 | $14,118 |
| ProcritEpoetin Alfa | 20 | $13,768 |
| ProsolParenteral Amino Acid 20% No.1 | 47 | $9,171 |
| Icosapent Ethyl | 18 | $4,035 |
| Hydralazine Hcl | 130 | $1,111 |
| Potassium Citrate ErPotassium Citrate | 16 | $1,074 |
| Calcium Acetate | 20 | $1,060 |
| Clonidine | 15 | $640 |
| Nifedipine ErNifedipine | 21 | $548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan | $106 | $252,56315 claims |
| Boehringer IngelheimJardiance | $53 | $60,67056 claims |
| Fresenius USA Marketing, Inc.Velphoro | $147 | $37,96015 claims |
| BayerKerendia | $440 | $26,68235 claims |
| AstraZenecaFarxiga | $77,344 | $17,58115 claims |
| Novo NordiskRybelsus | $102 | $14,11813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,341 nephrology providers in California.
Other nephrology in Glendale
- Raffi MinasianGlendale$1.5M
- Sam DaneshvariGlendale$1.1M
- Artashes PatrikyanGlendale$950K
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.